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Opioids are one of the most important arsenals 
armamentarium of physicians for fighting against pain. 
During the decades, opioids have been used in a wide 
range of indications; both for treatment of acute and 
chronic pain; as natural and synthetic compounds and in 
a variety of delivery forms from intravenous infusion to 
intrathecal adjuvants of local anesthetics or as 
transdermal patches (1-7). 
However, opioids as we know are not harm free 
drugs with a number of side effects attributable to them. 
There are very strong concerns regarding the risk of 
opioid dependence. Currently, in the United States, more 
than millions of people worldwide are involved with 
opioid abuse, often as the aftermath of acute or chronic 
pain management. The US CDC (Centers for Disease 
Control and Prevention) has announced that the US has 
reached and epidemic level regarding opioid abuse; 
leading to increased frequency of opioid abuse and 
opioid related death (2, 6-8). Currently, the following 
topics are quoted as the main reasons leading to this 
devastating epidemic: 
 Irrational practice in opioid 
prescriptionAscensional trend in opioid 
prescription and misuse  
 Increasing trend of illegal or illicit opioid misuse 
 Illicit opioid overdose-related deaths 
 Ease of access to opioids as highly addictive agents 
All stakeholders; including medical care 
providers, researchers in the field of medicine, 
surveillance bodies and most importantly, policy makers 
including high rank decision makers are seriously 
concerned with the recent increased trend of opioid use 
in the US (4, 5, 9, 10). The issue is that on one side, we 
have to help patients suffering pain especially acute 
perioperative pain and on the other hand, we are faced 
with an increasing trend of opioid abuse partially due to 
opioid dependence after acute pain relief using opioids 
(4, 5, 8-11). 
How can we get rid of this epidemic while we 
impose no more harm to the patients suffering acute or 
chronic pain? As we know, getting rid of this problem 
need a well-designed strategic planning; this is well 
beyond the scope of this editorial. However, one of the 
main steps in this strategy is to create alternative 
pathways to bypass opioid use in acute and chronic pain 
control. The role of emerging drugs is a real promise. 
Acute and chronic pain control without opioid use is 
now an attainable objective in the current era of cellular 
and molecular medicine (12-15). 
In this volume of JCMA, a number of studies are 
published that directly aim the goals of the above 
strategic planning in harm reduction, through 
introducing novel analgesic methods; these studies 
replace opioids with novel non-opioid drugs in 
controlling pain totally or partially (16-20). Taheri et al, 
Moshari et al and Aghadavoudi et al deal with acute pain 
management using opioid sparing methods; with a 
partial or total replacement of opioids with non-opioids 
(16-18). On the other hand, Taherian et al, represent 
their study demonstrating cellular and molecular 
mechanisms of pain alleviating properties of Malva 
neglecta on Expression of Inflammatory Biomarkers in 
patients with chronic crippling pain (19) while Alipour 
et al present an integrated basic/clinical review dealing 
with the future novelty windows for pain control based 
on biologic mechanisms especially considering the role 
of gut microbiota (20). Of course, there are a number of 
pioneering ideas and qualified studies published in the 
previous issues of JCMA and other journals that could 
effectively lead us to new promising pathways in opioid-
free pain control approaches (3, 12-15, 21-25). 
There is no doubt that we are in an opioid misuse 
epidemic status; whether in the US or other countries; 
but if we want to resolve this miserable multilateral 
complication, there is no doubt that Cellular and 
Molecular aspects of Anesthesia has a key role in 
resolving the problem; through creating an opioid free 
pain management era (8). 
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